Vir Biotechnology Inc. (VIR)
NASDAQ
Real-time Data
01:30 PM
Day's Range
9.4452 wk Range
4.35Overview - VIR - Vir Biotechnology Inc.
Key Statistics
Valuation
Enterprise Value
1.23B
P/E (Trailing)
‪-3.13‬
P/E (Forward)
‪-3.97‬
PEG Ratio
‪0.01‬
Price / Sales (TTM)
‪5.53‬
Price / Book
‪1.96‬
EV / EBITDA
‪-4.61‬
Profitability
Gross Margin
‪100.00%‬
Profit Margin
‪-83.00%‬
Operating Margin
‪30.74%‬
Return on Assets
‪-14.51%‬
Return on Equity
‪-26.08%‬
Ownership
Shares Outstanding
169.18M
Float
129.79M
Short % of Shares Outstanding
‪11.39%‬
Held by Insiders
‪6.56%‬
Held by Institutions
‪84.25%‬
Price stats
Beta
‪1.59‬
50-Day Avg
‪9.40‬
200-Day Avg
‪8.33‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
10 analysts
Average price target
‪$ 21.00‬Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - VIR - Vir Biotechnology Inc.
Peers - VIR - Vir Biotechnology Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- VIRNASDAQVir Biotechnology Inc.1.55BMarket Cap+53.27%52-week change-3.10P/E (Trailing)‪-83.00%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt62.93BMarket Cap+33.08%52-week change39.69P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.58BMarket Cap-87.93%52-week change40.23P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE28.34BMarket Cap+7.12%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.61BMarket Cap+23.98%52-week change19.38P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.84BMarket Cap+39.72%52-week change-21.44P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.59BMarket Cap+11.71%52-week change180.27P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - VIR - Vir Biotechnology Inc.
About
Vir Biotechnology Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and advances immune-based therapies to treat and prevent serious infectious diseases and cancer. The company leverages its next-generation antibody platform and PRO-XTEN protease-releasable masking technology to power the…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
